|
Deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide's metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can't cross the blood-brain barrier, it reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.
At Clearsynth, we understand you are working on Enzalutamide and we are here to help you by supplying the products you require for the research. Please contact us for more details.
|
